A Passion for Science and a Commitment to Dermatology

Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in medical dermatology. Dermavant leverages the Roivant platform to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development.

Dermavant Voices: Patient‑Focused Innovation

“THE ABILITY TO TRANSFORM LIVES”

Todd Zavodnick, Chief Executive Officer

“A PASSION FOR HELPING PEOPLE”

 Philip M Brown, MD, JD, Chief Medical Officer

“FUNDAMENTALLY CHANGING THE LIVES OF PATIENTS”

David Rubenstein, MD, PhD, Chief Scientific Officer

Latest News

January 22, 2020

Dermavant Appoints Chris Chapman as Chief Commerci ...

Read More

January 15, 2020

Dermavant Enters into Exclusive License Agreement ...

Read More

December 3, 2019

Dermavant Announces First Patient Dosed in Phase 2 ...

Read More